Obesity
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026Cardiology, EnteroBiotix, GSK, Obesity, Pharmacy, appointments, approvals
EnteroBiotix has appointed Dr Murray Stewart, former Chief Medical Officer at GSK and Rhythm Pharmaceuticals, to its Board of Directors. …
AI: an early warning system for patient safety
November 3, 2026AI, Cardiology, Diabetes, Diagnostics, Obesity, Pharmacy, chronic disease, chronic pain, pharmacovigilance
By Sanjeev Sachdeva Safeguarding patient health is the foremost responsibility of the pharmaceutical sector. While every medicine undergoes rigorous clinical …
Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison
October 23, 2026Diabetes, Obesity, Peptide therapies, clinical trials, diabetes, weight reduction
Pharmaceutical firm Lilly’s orforglipron was associated with greater reductions in body weight and blood glucose than oral semaglutide in adults …
Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial
October 6, 2026Diabetes, GLP-1, Obesity, diabetes, obesity, phase 3 trial
Boehringer Ingelheim’s investigational survodutide produced weight loss of up to 13.1% after 76 weeks in people with obesity or overweight …
Lilly reports positive results from trial of obesity candidate
August 8, 2025Medical Communications, Research and Development Eli Lilly and Company, Obesity, cardiovascular risk, high blood pressure, obesity
Eli Lilly and Company (Lilly) has announced topline results from its phase 3 ATTAIN-1 trial, showing that orforglipron – a …
MetP Pharma releases positive data on intranasal semaglutide administration
July 22, 2025Research and Development Diabetes, MetP Pharma, Neurology, Obesity, central nervous system, diabetes, obesity, peptides, semaglutide
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering neuroactive peptides, particularly semaglutide, directly …
Ciloa secures €6.5m from French government to advance obesity and T2 diabetes therapy
July 9, 2025Research and Development Ciloa, Diabetes, France 2030, Obesity, adiponectin, funding, obesity, type 2 diabetes
French biotech company, Ciloa, has received €6.5m in funding through France 2030 to advance its lead candidate, APN-sEV, targeting obesity …
Pila Pharma raises SEK 20m to advance new oral obesity treatment
July 8, 2025Research and Development Novo Nordisk, Obesity, Ozempic, Pila Pharma, Wegovy, obesity, semaglutide, type 2 diabetes
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital increase to advance the development …
Novo Nordisk’s therapy delivers significant weight loss in trial
June 25, 2025Research and Development Novo Nordisk, Obesity, obesity, weight loss, weight-related medical conditions
Novo Nordisk has announced promising results from its phase 3 REDEFINE 1 trial, showing that investigational weight loss therapy, CagriSema, …
Novo Nordisk unveils new semaglutide data on obesity and heart disease at ECO 2025
May 12, 2025Research and Development Cardiology, Novo Nordisk, Obesity, Ozempic, cardiometabolic conditions, heart disease, obesity, semaglutide
Danish biopharma, Novo Nordisk, has announced that it will present new data on metabolic and cardiovascular health at the upcoming …
Pfizer selects once-daily obesity drug for advancement
July 12, 2024Research and Development Obesity, Pfizer Inc, clinical trials, obesity
Pfizer has announced the selection of its preferred once-daily modified release formulation for danuglipron, with a plan to conduct dose …
Biophytis gains IND approval from FDA for obesity study
July 11, 2024Medical Communications Biophytis, IND, Obesity, clinical trial, obesity
Biophytis has announced that it has received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) …
Veru announces first patients enrolled in phase 2b trial for weight loss treatment
May 1, 2024Research and Development Obesity, Veru, Wegovy, enobosarm, weight loss
Veru has announced that it has enrolled the first patients into its phase 2b clinical trial of enobosarm, an oral …
Lipocine announces results from phase 2 trial for obesity drug
April 12, 2024Research and Development Lipocine, Obesity, clinical trial, weight loss
Lipocine Inc has announced results from its phase 2 clinical trial (NCT04134091), which includes results for LPCN 2401, the company’s …
Eli Lilly launches digital healthcare process
January 5, 2024Medical Communications Diabetes, Eli Lilly, Obesity, diabetes, obesity
Eli Lilly has announced its new digital healthcare experience, LillyDirect, which will benefit patients in the US with obesity, migraine …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
Coriolis Pharma appoints Teun van der Heide as CEO
The evidence bar impacting UK medical cannabis access
